<DOC>
	<DOCNO>NCT00783484</DOCNO>
	<brief_summary>First human study evaluate safety , tolerability , pharmacokinetics PF-03716539 . The potential PF-03716539 increase concentration midazolam , darunavir maraviroc also evaluate .</brief_summary>
	<brief_title>A Study To Evaluate The Safety , Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Body Mass Index ( BMI ) approximately 18 30 kg/m2 . Total body weight &gt; 50 kg ( 110 lb ) . Pregnant nursing female . female childbearing potential . Evidence history clinically significant hematological , renal ( include kidney stone ) , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) clinical finding screen . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>First Human ( FIH ) , PF-03716539 , PK enhancer</keyword>
</DOC>